

Central African Republic

Tuberculosis profile

Population 2015

4.9 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	2.2 (1.3–3.4)	45 (26–70)
Mortality (HIV+TB only)	2.7 (1–5.3)	55 (20–107)
Incidence (includes HIV+TB)	19 (12–27)	391 (253–558)
Incidence (HIV+TB only)	8.6 (5.3–13)	176 (107–262)
Incidence (MDR/RR-TB)**	0.21 (0–0.45)	4.3 (0–9.2)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	1.3 (0.63–1.9)	7.2 (3.6–11)	8.4 (4.2–13)
Males	1 (0.59–1.4)	9.7 (6.6–13)	11 (7.2–14)
Total	2.3 (1.4–3.1)	17 (13–21)	19 (12–27)

TB case notifications, 2015

Total cases notified	10 799
Total new and relapse	10 459
- % tested with rapid diagnostics at time of diagnosis	1%
- % with known HIV status	48%
- % pulmonary	82%
- % bacteriologically confirmed among pulmonary	61%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	55% (38–84)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.27 (0.13–0.48)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	1 963	39%
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			140 (23–250)
Estimated % of TB cases with MDR/RR-TB	0.4% (0–1.6)	14% (6.9–21)	
% notified tested for rifampicin resistance	<1%	14%	105
MDR/RR-TB cases tested for resistance to second-line drugs			38
Laboratory-confirmed cases		MDR/RR-TB: 62, XDR-TB: 2	
Patients started on treatment ****		MDR/RR-TB: 38, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2014	70%	9 209
Previously treated cases registered in 2014	64%	476
HIV-positive TB cases, all types, registered in 2014	68%	2 056
MDR/RR-TB cases started on second-line treatment in 2013	81%	16
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	1.8
Funding source: 15% domestic, 55% international, 31% unfunded	


* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history


**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




Incidence


Notified (new and relapse)

Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



New cases


Previously treated cases

HIV-positive

MDR/RR-TB

XDR-TB

Total budget (US\$ millions)



Unfunded

Funded internationally

Funded domestically